<< BACK to Press Releases
Epizyme to Present at Lazard Capital Markets Healthcare Conference
Cambridge, MA, November 9, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced that Mr. Jason Rhodes, Executive Vice President and Chief Business Officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011 at 1:00 PM EST in Grand Ballroom A of The Pierre Hotel, located at 2 East 61st Street, New York.
Epizyme’s therapeutics discovery programs are focused on histone methyltransferases (HMTs), a class of epigenetic enzymes that play an important role in regulating pathways of genes that are strongly associated with the underlying causes of many human diseases, including cancer. Epizyme announced a program-based partnership with Eisai for the epigenetic enzyme EZH2 in March 2011 and a multi-target drug discovery alliance with GlaxoSmithKline in January 2011.
Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com
Kari Watson or
MacDougall Biomedical Communications